← Intra-Cellular Therapies, Inc. (ITCI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Intra-Cellular Therapies, Inc. (ITCI)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-03-16 (est.)
Phase 2
Pipeline
14
programs
Upcoming events
4
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2027-03-16 (est.)Phase 2 · ITI-1284 10 mgimp 7/10
- 2027-04-05 (est.)Phase 3 · Lumateperoneimp 9/10
- 2027-06-21 (est.)Phase 3 · Lumateperone low doseimp 9/10
- 2027-06-21 (est.)Phase 3 · Lumateperone high doseimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Lumateperone high dose | Phase 3 | Irritability Associated With Autism Spectrum Disorder |
| ITI-007 | Phase 3 | Schizophrenia |
| ITI-1284 20 mg | Phase 2 | Generalized Anxiety Disorder |
| ITI-007 (Lumateperone) | Phase 3 | Bipolar Depression |
| Lenrispodun | Phase 2 | Parkinson Disease |
| ITI-1284 10 mg | Phase 2 | Generalized Anxiety Disorder |
| Lumateperone | Phase 3 | Major Depressive Disorder |
| Lumateperone low dose | Phase 3 | Irritability Associated With Autism Spectrum Disorder |
| ITI-214 | Phase 2 | Heart Failure, Systolic |
| Lumateperone 42 mg | Phase 3 | Schizophrenia |
| Lumateperone (ITI-007) | Phase 3 | Bipolar Depression |
| ITI-1284 | Phase 3 | Agitation Associated With Alzheimer's Dementia |
| Caplyta | Phase 2 | Borderline Personality Disorder |
| Risperidone | Phase 2 | Schizophrenia |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ITCI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.